The ALNY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALNY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ALNY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ALNY Detailed Price Forecast - CNN Money||View ALNY Detailed Summary - Google Finance|
|View ALNY Detailed Summary - Yahoo! Finance||View ALNY Stock Research & Analysis - Zacks.com|
|View ALNY Trends & Analysis - Trade-Ideas||View ALNY Major Holders - Barrons|
|View ALNY Call Transcripts - NASDAQ||View ALNY Breaking News & Analysis - Seeking Alpha|
|View ALNY Annual Report - CompanySpotlight.com||View ALNY OTC Short Report - OTCShortReport.com|
|View ALNY Fundamentals - TradeKing||View ALNY SEC Filings - Bar Chart|
|View Historical Prices for ALNY - The WSJ||View Performance/Total Return for ALNY - Morningstar|
|View the Analyst Estimates for ALNY - MarketWatch||View the Earnings History for ALNY - CNBC|
|View the ALNY Earnings - StockMarketWatch||View ALNY Buy or Sell Recommendations - MacroAxis|
|View the ALNY Bullish Patterns - American Bulls||View ALNY Short Pain Metrics - ShortPainBot.com|
|View ALNY Stock Mentions - StockTwits||View ALNY Stock Mentions - PennyStockTweets|
|View ALNY Stock Mentions - Twitter||View ALNY Investment Forum News - Investor Hub|
|View ALNY Stock Mentions - Yahoo! Message Board||View ALNY Stock Mentions - Seeking Alpha|
|View Insider Transactions for ALNY - SECform4.com||View Insider Transactions for ALNY - Insider Cow|
|View ALNY Major Holdings Summary - CNBC||View Insider Disclosure for ALNY - OTC Markets|
|View Insider Transactions for ALNY - Yahoo! Finance||View Institutional Holdings for ALNY - NASDAQ|
|View ALNY Stock Insight & Charts - FinViz.com||View ALNY Investment Charts - StockCharts.com|
|View ALNY Stock Overview & Charts - BarChart||View ALNY User Generated Charts - Trading View|
Top 10 Healthcare Stories of 2018
Posted on Thursday December 13, 2018
New drugs, trial flops, M&A, and a little bit of everything else that happened in healthcare in 2018.
Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Array BioPharma
Posted on Thursday December 13, 2018
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Posted on Monday December 10, 2018
Here are five stocks that are attractive and most likely to be takeout targets in 2019.
Alnylam Announces Settlement of Litigation with Silence Therapeutics
Posted on Sunday December 09, 2018
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it has resolved all litigation worldwide with Silence Therapeutics. The settlement allows Alnylam to avoid the costs and distraction associated with continued litigation in multiple countries. Under terms of the global settlement, Silence will receive a low royalty on annual net sales of ONPATTRO in the EU only, with tiered royalties of 0.33 percent to 1.0 percent through 2023. Further terms of the agreement include the grant from Silence to Alnylam of a non-exclusive, global irrevocable, license to all relevant patents and for all current and future Alnylam products, whether commercialized by Alnylam or a collaborator or licensee (including ONPATTRO, vutrisiran, givosiran, lumasiran, inclisiran, fitusiran, cemdisiran, ALN-HBV02, ALN-AAT02, and all other investigational therapeutics in Alnylam’s current and future pipeline).